Sangamo Therapeutics, Inc..
SGMO.US | Research and experimental development on natural sciences and engineering
Sangamo Therapeutics, Inc. is a genomic medicine company. It focuses on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. The company's lead programs are ...Show More
Better Health for All
20
Sangamo Therapeutics focuses entirely on developing genomic medicines for serious and rare diseases, aiming to replace symptomatic treatments with cures and transform patients' lives.
1
Clinical data for their Fabry disease gene therapy showed significant positive outcomes, including a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks, stable cardiac function, and maintained elevated alpha-galactosidase A activity for up to 4.5 years, allowing all 18 patients on ERT to discontinue it.
2
The company has no products with negative health outcomes. Sangamo emphasizes comprehensive risk disclosures, requiring clinical study teams to disclose all known risks, benefits, and alternative options through informed consent, and acknowledges the need for transparency regarding the lifelong nature of genomic medicines.
3
The company's entire R&D budget is dedicated to improving health outcomes, as its mission is to deliver genomic medicines.
4
Sangamo attended the 15th Annual Fabry Family Education Conference, bringing together over 200 Fabry patients and families to gather insights.
5
The company's updated Code of Conduct (December 1, 2022) includes clarification on data privacy and personal information, and it recognizes the importance of supporting patient access to individual health information.
6
Sangamo emphasizes informed consent as an ongoing, interactive discussion, working with patient advocacy stakeholders to ensure documents are developed with attention to language and literacy.
7
The company's operations are not directly relevant to patent flexibility, as it is a genomic medicine company focused on developing new therapies. Sangamo offers a Patient Resources page for educational materials to support patients.
8
Fair Money & Economic Opportunity
0
Sangamo Therapeutics, Inc. is a genomic medicine company, not a financial institution. The company's core business involves developing genomic medicines, not providing financial services such as lending, insurance, or money management to consumers. Therefore, the KPIs under the 'Fair Money & Economic Opportunity' value, which are specifically designed to assess financial institutions' impact on financial inclusion and economic opportunity, are not applicable to this company. The provided articles discuss internal diversity, equity, and inclusion efforts, employee benefits, and patient engagement, but these do not align with the specific financial services context of the rubric's KPIs. Consequently, no relevant evidence was found to score any of the KPIs.
Fair Pay & Worker Respect
30
In 2020, the ratio of the CEO's total compensation to the median employee's total compensation was approximately 22 to 1.
1
Employee reviews on Glassdoor indicate a 77% recommendation rate to a friend and a 71% CEO approval rating, with an overall employee rating of 3.8 out of 5 stars.
2
Executive officers are eligible to participate in all company benefit plans, including medical, dental, and vision, and the company pays life insurance premiums for named executive officers.
3
There were two late Form 4 reports filed by one executive, each disclosing one transaction in 2020, and several other executives and entities filed amendments to Form 4s for two transactions in 2020, along with one late Form 3 filing by Biogen Inc. and Biogen MA Inc.
4
Fair Trade & Ethical Sourcing
0
No specific quantitative data points related to fair trade and ethical sourcing, such as fair trade certification share, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend, were found in the provided articles for Sangamo Therapeutics (SGMO.US).
1
Honest & Fair Business
0
Sangamo Therapeutics has a formal Whistleblower Policy, launched in January 2021, which applies to all personnel and business partners worldwide.
1
This policy includes multiple reporting channels, an anonymous hotline staffed by an outside vendor, confidentiality, and explicit anti-retaliation provisions.
2
Reports are promptly reviewed and investigated, with accounting/auditing matters overseen by the Audit Committee.
3
The policy is communicated to all staff via the intranet and public website.
4
The company also maintains a comprehensive anti-corruption policy, with its Code of Conduct updated in December 2022 to include clarification on anti-bribery and anti-corruption laws.
5
The company represents that it has instituted, maintains, and enforces policies and procedures designed to ensure compliance with anti-bribery and anti-corruption laws, and that it and its personnel have not violated these laws or made unlawful payments.
6
The Sangamo Compliance & Ethics Hotline is staffed by an outside vendor, which provides some level of third-party involvement in the reporting mechanism.
7
Kind to Animals
-40
The company mentions adherence to "applicable requirements for the humane use of laboratory animals" during preclinical testing.
1
However, it does not explicitly state a formal animal testing policy.
2
The company consistently uses animal models, including mice and nonhuman primates, in preclinical studies for various product candidates, such as gene therapy constructs and prion disease research.
3
No War, No Weapons
0
No evidence available to assess Sangamo Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Sangamo Therapeutics, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence available to assess Sangamo Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-40
Sangamo Therapeutics experienced a data breach in 2018 where an executive's company email was accessed for 11 weeks, compromising sensitive and secret information.
1
The company does not maintain cyber liability insurance for such incidents.
2
While the company notified federal law enforcement, the incident itself and the lack of cyber liability insurance indicate a reactive posture and underinvestment.
3
Its updated Code of Conduct (December 2022) includes data privacy and personal information, and it provides ethics reporting mechanisms.
4
The company's privacy policy, last updated June 2023, outlines compliance with CCPA and European Privacy Laws, offering users rights to access, correct, and delete personal information, and opt-out of data sharing.
5
It states that Sangamo does not sell personal information for monetary consideration and collects data as necessary, retaining it as long as services are used or for the purposes collected.
6
Zero Waste & Sustainable Products
0
No evidence available to assess Sangamo Therapeutics, Inc. on Zero Waste & Sustainable Products.